

COUNTRY PROFILE **Switzerland**

Switzerland is a decentralised state. The division of tasks between the private and public sectors in the field of research and innovation has established itself over time and is based on two pillars of Swiss politics, namely subsidiarity and a liberal economy. The state is active in the areas where it has an explicit constitutional mandate. Education, research and innovation exist in a complex complementary system, in which different responsibilities and subject matters interlace. For further information about the Swiss R&I System and the roles of state, cantons and private sector, please check:

https://www.sbfi.admin.ch/sbfi/en/home/research-and-innovation/research-and-innovation-in-switzerland.html).

Switzerland combines robust public funding, active corporate venture capital, and international collaboration. Innosuisse, the Swiss Innovation Agency, funds applied R&D, startup coaching, and international collaborations. The Swiss National Science Foundation (SNSF) supports fundamental research and co-leads BRIDGE, a program fostering the transition from lab to market. ESA BIC Switzerland and Trust Valley add sector-specific instruments. Swiss-based entities also participate in Horizon Europe, granting access to a €95.5 billion EU research program. Global biotech leaders Novartis and Roche operate major venture arms from Switzerland. This multi-layered funding environment enables teams to grow and collaborate. Check Startupticker and the official SME Portal of the Federal Government for overviews about Startup, VC and Private Equity investors in Switzerland. (from Switzerland Innovation Park − Cutting-edge Technology and R&D Eco-system: Switzerland Innovation)

Switzerland has a Federal Act on Controlling Communicable Human Diseases (EpidA) see https://www.fedlex.admin.ch/eli/cc/2015/297/en

In July 2025 the revised National Pandemic Plan was published see https://www.bag.admin.ch/en/national-pandemic-plan-switzerland

Switzerland has different disease surveillance initiatives in place, and has different dashboards & visualization platforms, infrastructures and data sources related to pandemic preparedness see https://www.infectious-diseases-toolkit.org/national-resources/switzerland

In January 2025 the Centre for Pathogen Bioinformatics (CPB) was launched in Bern. https://www.sib.swiss/centre-for-pathogen-bioinformatics

Other research actors for clinical/epidemiological metadata are Clinical Bioinformatics group, SIB; Bacteriology and Virology Laboratories, University Hospitals of Geneva (Centre National de Référence des Infections Virales Emergentes - CRIVE & Centre des Maladies Virales Emergentes - CMVE); Microbiology Institute and Hospital Hygiene Unit, University Hospital of Lausanne; Clinical Microbiology and Clinical Virology, University Hospital of Basel; Infectious Diseases Institute and VetSuisse, University of Bern; Institute of Medical Microbiology, Institute of Medical Virology and VetSuisse, University of Zurich

R&I Policies and Strategies

The information is not exhaustive and should be updated regularly.

Country has a dedicated strategy for research and innovation related to pandemic threat? Yes R&I strategy URL https://www.bag.admin.ch/bag/en/home/krankheiten/ausbrueche-epidemien-pandemien.html
For the research financed by the SNSF: https://data.snf.ch/grants/documentation

Country has an open science portal with information on publicly financed scientific research? Yes https://www.aramis.admin.ch/

R&I portal for the research financed by the SNSF https://data.snf.ch/key-figures

Country has R&I webpage on CC

COVID-19; Antimicrobial resistance (AMR); Chemical, Biological, Radiological and Nuclear (CBRN)

threats; Other: https://www.bag.admin.ch/bag/en/home/das-bag/ressortforschung-evaluation.html

Website open science/ open data initiative with respect to pandemic threats, such as COVID-19 open

Short Description

COVID-19 Switzerland https://www.covid19.admin.ch/en/overview

GenSpectrum - Inspect pathogen genomic data https://genspectrum.org/

An interactive platform to help scientists and public health

professionals query and analyze pathogen sequences.

https://www.infectious-diseases-Infectious diseases toolkit Switzerland

toolkit.org/national-resources/switzerland

https://nextstrain.org/ Nextstrain Real-time tracking of pathogen evolution

Nextstrain is a project to harness the scientific and public health potential of pathogen genome data. Our goal is to aid epidemiological understanding of pathogen spread and

Yes

evolution and improve outbreak response.

Swiss Mosquito Network https://www.zanzare-svizzera.ch/en/about/

Country has coordinating structures to link public health needs and research needs? Yes

Coordinating structures URL https://www.newsd.admin.ch/newsd/message/attachments/82996.pdf

Please note: Document in German, French and Italian only

R&I Infrastructures

The information is not exhaustive and should be updated regularly.

Country has the following research infrastructure for infectious diseases and

BSL 3; BSL 4; Emergency intervention units; Clinical trial units; High level isolation units; High level isolation transport; Open genome deposits for outbreaks available, or under construction viruses; Open genome deposits for bacteria; Open genome deposits for AMR; Reference centres of excellence; Other (Swiss Biobanking Platform, Swiss personalized Health Network, Swiss Hiv Cohort Study, Swiss Hepatitis C Cohort Study, Pandemic preparedness population-based household cohort including adults, children and household pets) - not exhaustive

Name Infrastructure	Type Infrastructure	URL	Max Capacity	Available for	Open to
---------------------	---------------------	-----	--------------	---------------	---------

15 Reference centres List only available in DE,FR,IT

Reference centres of excellences

https://www.bag.admin.ch/bag

/en/home/krankheiten/infektionskrankheiten -bekaempfen/meldesysteme-infektionskrankheiten

/meldepflichtige-ik.html

BEready Cohort Population-based cohort Academia https://www.beready.unibe.ch/

which collects

questionnaire data and biological samples

Centre for Centre for https://www.sib.swiss/centrefor-pathogen-bioinformatics

Pathogen Bioinformatics (CPB)

DKF Basel, CTU Bern, CRC Clinical trial units

Geneva, CRC Lausanne, CTU-EOC Lugano, CTU St.

https://www.scto.ch/de/clinic al-trial-units.html

Gallen, CTC Zürich

Genome 2030 open genome deposit for

viruses and bacteria

Academia Yes https://www.health2030genome.ch/

HUG High level isolation units https://www.hug.ch

Spiez Laboratory BSL4 https://www.spiezlab.admin.c

h/en/home.html

Swiss Biobanking platform Independent Yes https://swissbiobanking.ch/

organisation

Swiss Center for Antibiotic Academia Yes https://www.anresis.ch/

Resistance (anresis)

Swiss Clinical Trial https://www.sctoplatforms.ch/ Organisation (SCTO)

Independent organisation

Yes

Swiss Hepatitis C Cohort

Study (SCCS)

https://www.swisshcv.org/

Swiss Hiv Cohort Study

(SHCS)

https://www.shcs.ch/

Swiss Pathogen (SPSP)

Open genome deposits for Surveillance Platform viruses, bacteria and for

https://www.spsp.ch/

Academia

Yes

Swiss Personalized Health

Network (SPHN)

High level isolation units

https://www.usz.ch/

https://sphn.ch/

Country supporting the participation to the following ESFRI initiatives relevant for infectious diseases

BBMRI; EATRIS;

ECRIN

USZ

Website network of clinical trials (e.g. to facilitate the access to clinical trials) the country is involved in

https://eu-response.eu/

https://ecrin.org/

https://www.ecraid.eu/

https://vaccelerate.eu

https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-

treatments

https://www.sctoplatforms.ch/

https://www.scto.ch/

https://www.combacte.com/

Budget mobilisation mechanisms and funding sources The information is not exhaustive and should be updated regularly.

Basic Research

url https://www.snf.ch/en/WAvYcY7awAUGolST/funding/projects/projects-in-all-disciplines

funding for basic research accessible for industry?

source of funding Public (research) agencies

Applied Research

funding for applied research accessible for industry? source of funding Public (research) agencies

Translational Research

url

funding accessible for industry? source of funding

Clinical Research in general & in pandemic phase

funding accessible for industry? source of funding phase funded?

Innovation Projects

url

https://www.innosuisse.ch/inno/de/home.html

funding for innovation projects accessible industry? Source of funding

Flexible funding during emergencies possible: Two National Research Programmes were launched to answer the challenges related to COVID19 https://www.snf.ch/en/ROoig00P3wqY8Sws/page/nrp/nrp78 see also https://data.snf.ch/stories/fast-tracking-solutions-to-the-coronavirus-pandemic-en.html

R&I actors, authorities and activated processes that are activated in case of a

 $\pmb{health\ threa\underline{t}}$ The information is not exhaustive and should be updated regularly.

R&I actors, authorities and

ministries involved in case of an outbreak; mobilisation processes of research forces; mechanisms to identify promising therapies or medical products for pandemic preparedness that are in the pipeline

Name Description url

Foundation for Innovative and New Diagnostics

The Foundation for Innovative and New Diagnostics is WHO Collaborating Centre for Laboratory Strengthening and Diagnostic **Technology Evaluation**

https://www.finddx.org/

Hôpitaux Universitaires de Genève (HUG)

HUG is WHO Collaborating Centre for epidemic and pandemic diseases and WHO Collaborating Centre on infection prevention and control and antimicrobial resistance

https://www.hug.ch/en/centre-emerging-viraldiseases/who-collaborating-centre

(IVI)

Institute of Virology and Immunology IVI, with sites in Mittelhäusern and Bern, is a research institute under the aegis of the Swiss Federal Food Safety and Veterinary Office (FSVO). It is the only high-security laboratory in Switzerland with the capacity to diagnose and research highly contagious animal diseases (such as foot-and-mouth disease or swine fever). The Swiss Rabies Centre in Bern is affiliated to the IVI. The mission of the IVI is to perform basic and applied research as an important basis for the control of animal diseases and zoonoses and for

www.edi.admin.ch

Spiez Laboratory

Spiez Laboratory, the Swiss Federal Institute for NBC-Protection, is a division of the Federal Office for Civil Protection. We provide services relating to arms control, protection measures, health and incident management for international organisations, authorities and the general population. The biocontainment lab in Spiez enables the handling of human pathogens of the hazard categories 3 and 4 and provides services in four core areas

https://www.spiezlab.admin.ch/en

State Secretariat for Education, Research and Innovation (SERI)

The SERI is the federal government's competence center for national and international issues of education, research and innovation policy. Together with our partners, we are committed to ensuring that Switzerland continues to have an efficient ERI sector in the future.

https://www.sbfi.admin.ch/sbfi/en/home.html

(FOPH)

Swiss Federal Office of Public Health As part of the Federal Department of Home Affairs, FOPH is responsible for public health in Switzerland; it develops Switzerland's health policy

https://www.bag.admin.ch/bag/en/home.html

Biosafety Centre, Institute for Infectious Diseases (IFIK) of

Biosecurity

Universität Bern is WHO Collaborating Centre for Biosafety and

Version September 2025

University of Bern



BE READY is responding to the call: HORIZON-HLTH-2021-DISEASE-04-06 "Building a European partnership for pandemic preparedness" under grant agreement 101057795. Starting date: 01.06.2022. | End Date 31.05.2025

https://www.ifik.unibe.ch/

BE READY PLUS is responding to the call: HORIZON-HLTH-2024-DISEASE-17 "Pandemic preparedness and response: Maintaining and enhancing the preparatory work for a co-funded European partnership for pandemic" under grant agreement 101195079. Starting date: 01.01.2025. Lend Date 31.12.2025

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA), under the powers delegated by the European Commission. Neither the European Union nor the granting authority can be held responsible for them.

This country profile is based on input received via https://ec.europa.eu/eusurvey/runner/BEREADY Questionnaire Observatory and desktop research and does not contain any private information